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1SUMMARY
The clinical development process can be viewed as a succession of trials, possibly overlapping in
calendar time. The design of each trial may be inﬂuenced by results from previous studies and other
currently proceeding trials as well as by external information. Results from all these trials must
be considered together in order to assess the eﬃcacy and safety of the proposed new treatment.
Meta-analysis techniques provide a formal way of combining the information. We examine how
such methods can be used in combining results: (1) from a collection of separate studies, (2) from
a sequence of studies in an organized development program, (3) from stages within a single study
using a (possibly adaptive) group sequential design. We present two examples. The ﬁrst concerns
the combining of results from a Phase IIb trial using several dose levels or treatment arms with
those of the Phase III trial comparing the treatment selected in Phase IIb against a control. This
enables a “seamless transition” from Phase IIb to Phase III. The second example examines the use
of combination tests to analyze data from an adaptive group sequential trial.
Key words: Adaptive designs; Clinical trials; Early data review; Flexible design; Group sequential
tests; Interim analysis; Meta-analysis; Overviews; Sample size re-estimation; Systematic reviews;
Two-stage procedure; Variance spending.
21 Introduction
The development process for a new drug often takes as long as ten to ﬁfteen years and can cost
over US$750 million. Hence any acceleration of the process, however slight, to identify beneﬁcial
or problematic drugs early can lead to large savings in economic cost and/or beneﬁts for human
health. The importance of this fact in the area of HIV prevention trials, for example, has been
emphasized recently by Padian (2004). The process consists of many stages from preclinical
laboratory and animal studies through to the various phases of clinical trials leading to review
by the FDA, or other regulatory body, of the New Drug Application. These stages are carried out
successively but typically may overlap in calendar time — see, for example, the CDER Handbook
(http://www.fda.gov/cder/handbook/develop.htm). At each stage, a decision must be made
whether to abandon or continue the process. This decision will be based on all available data from
preceding and current stages as well as any pertinent external information. If the decision is to
continue, then the next study is designed (patient population, drug dose, etc.) with the help of
results from the previous stages. This information is combined both in a formal and informal way. If
the studies are separate and independent, then various meta-analysis methods have been proposed
to provide a quantitative way to combine the results — see, for example, Hedges and Olkin (1985),
Sutton et al. (2000), Egger et al. (2001) or Whitehead (2002). As we shall see, certain meta-analysis
methods based on P-values remain valid even when the design of one study may depend on results
from other studies in the series.
Near the end of the process, the conﬁrmatory Phase III clinical trial is typically a large scale
multi-center trial involving a large number of patients. The trial lasts several years and it is now
becoming more customary to have interim monitoring performed by a data safety and monitoring
board (DSMB) — see, for example, the guidance in ICH E9 (FDA, 1998). A formal group sequential
design is often included in the trial protocol or in the DSMB charter. Over time, information, be it
blinded or unblinded, internal or external to the trial, accumulates and this may naturally indicate
worthwhile changes to be made to the trial design. A common change is sample size re-estimation
based on a better knowledge of a key nuisance parameter such as a response variance or a baseline
event rate. Such modiﬁcations to the design are often approved. In fact, this possibility and the
consequent re-estimation rule can be pre-speciﬁed in the design protocol. However, other design
modiﬁcations have been more problematic. Examples include changes in dosing levels or spacing,
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particular, changes in the designated target eﬀect size to be detected with the pre-speciﬁed power
(or equivalently a change in this stated power). As an example, Cui, Hung and Wang (1999)
described a trial for prevention of myocardial infarction where unexpected interim results revealed
a lack of power at a relevant alternative. Partly because of concerns about statistical validity, the
sponsor withdrew the request for a protocol modiﬁcation to increase the sample size and the trial
eventually ended with a negative conclusion. Recently there has been a lot of activity in the topic
of so-called adaptive group sequential designs. Basic papers on this subject include Bauer and
K¨ ohne (1994), Proschan and Hunsberger (1995), Fisher (1998), Cui et al. (1999), Lehmacher and
Wassmer (1999), Denne (2001) and M¨ uller and Sch¨ afer (2001). At the time of writing, we have
found over 100 papers in the literature on this subject. These proposals allow design modiﬁcations
at interim looks, planned or unplanned, while preserving the overall Type I error rate ®. However
this ﬂexibility can come at the cost of statistical eﬃciency — see, for example, Jennison and
Turnbull (2003), Tsiatis and Mehta (2003) and Posch, Bauer and Brannath (2003).
In this paper we examine how essentially the same “meta-analysis” methods can be used in
combining results: (1) from a collection of separate studies, (2) from a sequence of studies in an
organized development program, (3) from stages within a single study using a (possibly adaptive)
group sequential design. In the next section we review methods for testing a null hypothesis
based on several studies — so-called “combination tests”. The studies may not be independent.
In Section 3, we examine the properties of one of these methods, the weighted inverse normal
combination test, in more detail. In Section 4, we use graphical methods to compare various
combination tests. Sections 5 and 6 present two examples. The ﬁrst concerns the combining of
results from a Phase IIb trial using several dose levels or treatment arms with those of the Phase III
trial which compares the dose or treatment selected after Phase IIb with a control. This enables
a “seamless transition” from Phase IIb to Phase III. The second example examines the use of
combination tests to analyze data from an adaptive group sequential trial.
2 Testing a null hypothesis based on several studies
We start by supposing there is a null hypothesis of no treatment eﬀect that has been studied in
K(¸ 2) separate and independent experiments. Suppose that, for 1 · k · K, the treatment eﬀect
4in the kth experiment can be quantiﬁed by a real parameter µk such that the null hypothesis of
no treatment eﬀect is represented by H0k: µk = 0. We consider a one-sided alternative hypothesis
HAk: µk > 0. When combining studies, directions of deviations from each H0k are important and
hence use of a two-sided alternative is not very useful. The overall hypothesis of no treatment eﬀect
is the intersection
H0 = \K
k=1 H0k
which implies µk = 0 for each k = 1;:::;K. The alternative hypothesis HA is that at least one
µk > 0. We are seeking a P-value for testing the overall null hypothesis, H0, versus HA.
Goutis, Casella and Wells (1996) give a very general discussion on the use of P-values as a
means to assess evidence from multiple studies. In our situation, let Pk denote the P-value from
testing H0k in the kth study (1 · k · K). We shall assume Pk has the uniform distribution U(0;1)
under H0k. (This is generally the case, but may only be approximately true if the responses are
discrete or if H0k is composite — see Robins, van der Vaart and Ventura (2000).)
Becker (1994) has surveyed methodology for combining signiﬁcance levels and, in her Table 15.1,
she lists some eighteen diﬀerent proposals. Here we shall consider just a few that are commonly
used in the social science literature and are natural to use in the clinical trials context. The ﬁrst
such method is an inverse chi-square or “sum of the logs” method proposed by R. A. Fisher (1932).
Here an ®-level tests rejects H0 if
¡2log(P1P2 :::PK) > Â2
2K(®); (1)
where Â2
2K(®) denotes the upper ® percentage point of a chi-squared distribution with 2K
degrees of freedom. This follows because under H0 the fPkg are independent U(0;1) and so
¡logPk » Exp(1) » 1
2Â2
2. An overall P-value is deﬁned by ﬁnding that value of ® for which
equality is obtained in (1).
The most commonly used method in the social sciences is the inverse normal method (Stouﬀer
et al., 1949). Deﬁne Zk = Φ¡1(1 ¡ Pk) for k = 1;:::;K. Then under H0, each Zk » N(0;1) and
an ®-level test rejects H0 if
1
p
K
(Z1 + ::: + ZK) > z(®); (2)
where z(®) denotes the upper ® percentage point of a standard normal N(0,1) distribution. A
generalization proposed by Mosteller and Bush (1954) is the weighted inverse normal method
5whereby H0 is rejected at level ® if
w1Z1 + ::: + wKZK > z(®); (3)
where ﬁxed weights fwkg are chosen to satisfy
PK
k=1 w2
k = 1. Clearly the left hand side of (3) has
a standard normal distribution under H0.
In fact, Mosteller and Bush (1954) proposed diﬀerential weighting of the Z-values based on
sample sizes of the component studies. Hedges, Cooper and Bushman (1992) have pointed out that
the Z-values and P-values “are already weighted” in some sense and so such adjustment may not
be needed. However the rule (3) with weights based on sample sizes does have one very desirable
property which we shall discuss in the next section.
Not included in Becker’s (1994, Table 15.1) list, is the “maximum” combination test. This test
does appear in the list of Goutis et al. (1996, Table 1). Here the ®-level test rejects H0 if
max(P1;:::;PK) < ®1=K: (4)
The FDA’s “two pivotal trial” rule (FDA, 1995) can be considered a special case of this maximum
method in which K = 2 and both trials need to be signiﬁcant at the level 0:025 (one-sided) in
order for H0 to be rejected. Formally, as noted by Li and Huque (2003, p. 623), for example, this
joint requirement for the two trials is a strict one as it implies an overall signiﬁcance level for the
combination test of ® = 0:0252 = 0:000625. However, as pointed out by a referee, the object of
having two pivotal studies is not to require such a small signiﬁcance level but rather to ensure
replication of a ﬁnding that is not subject to systematic bias or fraud. Nevertheless, such extreme
P-values are of interest. Fleming and Richardson (2004, p. 668) quote instances where the FDA
has viewed evidence of treatment eﬀect with one-sided P-values in the range 0.0005 to 0.005 from
just a single trial to be “compelling” and perhaps obviating the need for a second trial. (Of course,
ﬁnal approval will depend on a number of other factors, internal and external to the study.)
Note that for any of the combination tests we have described, an overall P-value is deﬁned by
ﬁnding that value of ® for which equality is obtained in, respectively, (1), (2), (3) or (4).
Now, meta-analyses such as we have described are typically performed in order to obtain an
over-view of a collection of studies found in the literature. We shall consider a diﬀerent application:
using these methods to combine data formally from a series of studies making up a drug development
program. In following a program of studies, it is important to state at the outset which method
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embarking on a meta-analysis of a collection of published studies — otherwise, one could try a
number of the many diﬀerent methods and pick the one giving the lowest combined P-value! In a
program of research, the results of previous studies help determine the nature of the next study,
including its sample size, and so the studies cannot be considered independent. (The same can
be true for a collection of published studies but this feature is typically ignored!) This lack of
independence means there is a danger, under some of the combination rules, that this can lead to
inﬂation of the Type I error rate of the combination test.
Consider ﬁrst the inverse Â2 test (1). Note that the fPkg are statistically independent under
H0 even if the results from one study are used to design another. This is because each has a
U(0;1) conditional distribution. (To be rigorous, we need to be able to apply Theorem 2 of Liu,
Proschan and Pledger (2002). To invoke their theorem we note that, in any practical application,
their measurability conditions will hold; and we have assumed that the P-values are continuous and
uniformly U(0;1) distributed under H0.) Hence (1) remains an ®-level test and the corresponding
P-value remains valid. However, the fPkg are not necessarily statistically independent under HA.
Combination tests can be used recursively. Suppose initially it is decided that there will be
K = 2 studies and rule (1) will be employed. After observing the results and the P-value P1 of the
ﬁrst study, it is decided to run two further studies rather than one, resulting in observed P-values
Q1 and Q2, say. Then P2 is deﬁned as the solution to ¡2log(Q1Q2) = Â2
4(P2). Applying the
original rule, P1 and P2 are combined using (1) with K = 2. Note this is not the same as using (1)
with K = 3 and P-values P1, Q1 and Q2 and the latter approach would not give a valid ®-level
test. This illustrates the importance of pre-specifying K and the combination rule for P1;:::;PK.
There is an obvious generalization to K ¸ 2 of this recursive strategy.
Now we turn to the inverse normal method (2). Under H0, each Zk » N(0;1) and, by the same
reasoning as we used above for the P-values, the fZkg are statistically independent — even if the
results from one study are used to design another. To illustrate recursive use of (2), suppose that
K = 2 is pre-speciﬁed but after observing Z1 it is decided to run M(Z1) additional studies instead
of one, resulting in Z-values ˜ Z1;:::; ˜ ZM(Z1). Let Z2 = ( ˜ Z1 + ::: + ˜ ZM(Z1))=
p
M(Z1), then, by ﬁrst
conditioning on Z1, it is evident that (Z1 +Z2)=
p
2 is still standard normal under H0. However, if
we incorrectly ignore the dependence of M on Z1 and naively apply (2) with K = M, the resulting
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p
1 + M(Z1) and this is not standard normal under H0. If
M(Z1) = 1 as originally speciﬁed, the two statistics coincide.
For ﬁxed K and weights w1;:::;wK with
P
w2
k = 1, the weighted inverse normal test (3) retains
level ® if the results from one study are used to design another, for example, the sample size of
study k may be inﬂuenced by the previously observed Z1;:::;Zk¡1. Suppose, as in the previous
paragraph, that K = 2 and after observing Z1 it is decided to replace the second study by M(Z1)
studies resulting in Z-values ˜ Z1;:::; ˜ ZM(Z1). Suppose also that, before commencing the M(Z1)
studies, weights ˜ w1;:::; ˜ wM(Z1) depending on Z1 are speciﬁed and these satisfy ˜ w2
1+:::+ ˜ w2
M(Z1) =
w2
2. The test statistic (3) is still w1Z1 + w2Z2, where now w2Z2 = ˜ w1 ˜ Z1 + ::: + ˜ wM(Z1) ˜ ZM(Z1).
This idea can be applied recursively and one can use such a recursive construction to show the
test (3) retains level ® if, for k = 2;:::;K, the weights wk = wk(Z1;:::;Zk¡1) are allowed to
depend on previous outcomes (technically, they should be measurable functions — Liu, Proschan
and Pledger (2002)). Moreover, the number of terms, K, can itself be response-dependent. The
freedom to deﬁne the number of terms and their associated weights “adaptively” in this way provides
a signiﬁcant extension to the method. L. Fisher (1998) has termed this approach variance spending
and proposed it as a method for designing adaptive group sequential trials: each choice of a weight
wk “spends” an amount w2
k of the variance of ﬁnal Z-statistic and the study terminates when this
total reaches 1. The conditions on how weights in adaptive designs can be deﬁned are crucial if the
speciﬁed Type I error probability is to be achieved. If K = 2, the condition w2
1 + w2
2 = 1 implies
there is no freedom to change the originally speciﬁed w1 and w2 after observing Z1. Proschan and
Hunsberger (1995) present a cautionary example of a two-stage adaptive design which breaks this
rule since the second group size depends on Z1 and weights w1 and w2 are set proportional to the
square roots of the group sizes: for certain sampling rules, the Type I error of the test given by (3)
is in excess of 2®!
The development of Fisher’s (1998) variance spending designs illustrates how methods for
combined inference based on several separate studies can be applied to combine data from separate
stages of a single study. A multi-stage study in which the design of each stage can depend on
results of previous stages is termed an “adaptive” or “ﬂexible” procedure. Use of the inverse Â2
test (1) in this context was ﬁrst advocated by Bauer (1989) and Bauer and K¨ ohne (1994), whereas
an adaptive version of the weighted inverse normal test (3) was ﬁrst proposed by Fisher (1998).
83 Combining n paired diﬀerences
Consider ﬁrst a simple example of a balanced parallel arm trial with 2n patients treated in K
diﬀerent centers. In center k, 1 · k · K, immediate continuous responses fXA1k;XA2k;:::g
and fXB1k;XB2k;:::g are available on treatment arms A and B, respectively. The responses are
assumed to be independent from normal distributions N(¹A + ºk;¾2) and N(¹B + ºk;¾2). We
shall take the common variance ¾2 to be known and, without loss of generality, equal to 1
2. Hence
the diﬀerences Xik = XAik ¡ XBik are independent and identically distributed (i. i. d.) as N(µ;1)
where µ = ¹A ¡ ¹B is the parameter of interest. The goal is to test the null hypothesis µ = 0
versus the one-sided alternative µ > 0 with pre-speciﬁed Type I error rate ®. Although this seems
a very simple and restrictive example, by embedding the partial sums of the paired diﬀerences
into a Brownian motion and working with information rather than sample size, the techniques for
this prototype example can be applied in a wide variety of realistic applications. These include
other designs, such as crossover or longitudinal trials, and other endpoints, for example, binary or
survival data, ﬁtted to generalized linear models or Cox’s proportional hazards regression model;
for details see Jennison and Turnbull (2000, Chap. 3).
Suppose we have a ﬁxed total of n paired diﬀerences Xik, 1 · i · mk;1 · k · K, where there
are m1 pairs in the ﬁrst center, m2 in the second and so on, and n =
PK
k=1 mk. The Z-statistic
from center k is given by
Zk =
1
p
mk
(X1k + ::: + Xmkk); 1 · k · K:
A test of the hypothesis H0: µ = 0 could be carried out by combining P-values of tests based on
the data from each of the K individual centers using one of the methods described in Section 2.
Alternatively since the fXikg are i. i. d., the hypothesis H0 can be tested using the overall Z-statistic
for the total sample,
Z =
1
p
n
K X
k=1
mk X
i=1
Xik: (5)
In general these two tests will lead to diﬀerent results. However, they will concur if we use the
weighted inverse normal combination statistic (3) with weights wk =
p
mk=n. In this case, the
value of Z from (5) is identical to that in (3). This means we obtain the same test of H0, whether
we consider this as one study or as a combination of K component sub-studies — as long as we use
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study sample sizes. This property does not obtain for other combination methods. An important
property of Z here is that it is a function of the suﬃcient statistic
PK
k=1
Pmk
i=1 Xik, weighting each
paired diﬀerence equally. This means that the procedure is statistically eﬃcient.
Notice also that this combination test (and this one only) is invariant to an arbitrary partition of
the data. Suppose we wish to use data from this multi-center study to play the role of “two pivotal
studies” to meet the FDA’s rule referred to in Section 2. Suppose also it is agreed that it will suﬃce
to achieve some stated overall signiﬁcance level when results from the two sub-studies are combined
in a weighted inverse normal test with weights proportional to the square roots of the sub-study
sample sizes. We might choose to take the ﬁrst K=2 centers to make up Study 1 and the remainder
to make up Study 2. Alternatively, one could take the odd numbered centers for Study 1 and the
even ones for Study 2. Whatever arbitrary way the observations are partitioned into components,
the Z-statistic (3) remains unchanged when using the inverse normal combination test with weights
proportional to the square roots of sub-study sample sizes. This should be reassuring to a reviewer
who might otherwise be concerned there could be bias caused by a selectively chosen partition of
the data.
Note that, as argued in Section 2, this weighted combination rule will not maintain the Type I
error rate ® if the sample size in one sub-study can depend on results of others. Some other
combination method must be used, such as an inverse normal test with ﬁxed weights or the inverse
Â2 test. But we then lose the eﬃciency beneﬁts resulting from use of a suﬃcient statistic as well
as the comfort of having a test that is invariant to diﬀerent ways of partitioning of the data into
sub-studies. From this, we see there is a tension between having the ﬂexibility to design trials
adaptively and being able to use the most natural test statistic for the inference — all driven by
the requirement to maintain a ﬁxed overall Type I error probability.
4 A graphical description of combination tests
We consider the combination tests of Section 2 for the case K = 2. We choose this case for simplicity
but similar results can be envisioned for K ¸ 3. Proschan (2003) has also exploited a graphical
representation of two-stage tests in order to show their connection to positive quadrant tests.
We shall think of the two studies as ordered with Study 1 starting before Study 2, although
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their conduct can overlap chronologically. Recall that under H0, the P-values P1 and P2 have
independent U(0;1) distributions. The range of (P1;P2) is the unit square [0;1] £ [0;1] and an ®
level test rejects H0 if (P1;P2) 2 C, where the critical region C can be any subset of the unit square
with area ®. The combination tests vary only with respect to the choice of this subset.
Our ﬁrst example, Fisher’s inverse Â2 test, rejects H0 if
P1 ¢ P2 · c® = exp(¡
1
2
¢ Â2
4(®)): (6)
The weighted inverse normal test rejects H0 if
p
r Φ¡1(1 ¡ P1) +
p
1 ¡ r Φ¡1(1 ¡ P2) ¸ z(®); (7)
where r = w2
1 = 1 ¡ w2
2 and, thus, 0 < r < 1. These rejection regions are illustrated in Figure 1.
The ﬁgure for the inverse normal test shows the unweighted case, for which r = 0:5.
Note that the inverse Â2 test will always reject H0 if either P1 or P2 · c®. Thus, if P1 · c®,
there is no need to examine P2 or even conduct the second study — rejection of H0 is inevitable.
No such curtailment is possible with the inverse normal test.
We can transform the axes in Figure 1 to a probit scale by plotting (Z1;Z2) where Zk =
Φ¡1(1 ¡ Pk) for k = 1 and 2. On this scale the critical regions for our two combination tests are
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shown in Figure 2. Note that the boundary becomes linear for the inverse normal combination test.
Here again, the inverse Â2 test will always reject H0 if either Z1 or Z2 ¸ Φ¡1(1 ¡ c®).
Let us deﬁne the boundary of the critical region of a combination test like those in Figure 1 by
the equation P2 = ˜ A(P1). For the inverse Â2 test, we have
˜ A(p1) =
8
> <
> :
c®=p1 for c® < p1 · 1;
1 for 0 · p1 · c®:
For the inverse normal combination test, we have
˜ A(p1) = Φ
Ãp
rΦ¡1(1 ¡ p1) ¡ z(®)
p
1 ¡ r
!
:
Note that, because the critical region has area ®, the function ˜ A must satisfy
Z 1
0
˜ A(p1)dp1 = ®: (8)
Any non-increasing function ˜ A(p) taking values on [0;1] and satisfying (8) is termed a conditional
(Type I) error function. The hypothesis H0 is rejected if and only if the second study P-value,
P2, is less than ˜ A(P1). In other words, the hypothesis test for the second study is carried out at
signiﬁcance level ˜ A(P1). The condition (8) ensures that the unconditional Type I error is ®, as
required. The design of the second study does not have to be decided in advance of the results
of the ﬁrst study as long as signiﬁcance level ˜ A(P1) is used. This connection with the conditional
12error probability has been pointed out by Posch and Bauer (1999), Wassmer (2000, Sec. 3.1.3) and
Proschan (2003) among others.
There are of course many other choices for a conditional error function ˜ A(P1). Proschan and
Hunsberger (1995) proposed a “circular” conditional error function given by
˜ A(p1) =
8
> > > > <
> > > > :
1 for p1 · c;
1 ¡ Φ(
p
f(Φ¡1(1 ¡ c))2 ¡ (Φ¡1(1 ¡ p1))2g) for c < p1 < d;
0 for p1 ¸ d;
where c and d are constants chosen to satisfy (8). Using this conditional error function, the second
study is not needed if either P1 < c, for then H0 is inevitably rejected (signiﬁcance), or P1 > d,
in which case it is impossible for H0 to be rejected and one may stop for futility if such a P1 is
observed.
It is possible to modify the the inverse Â2 and normal combination tests (6) and (7) so that they
too have these curtailment features. Bauer and K¨ ohne (1994) modify the inverse Â2 rule to allow
stopping for futility after only the ﬁrst study. This occurs if P1 > d and the increased probability
of accepting H0 is balanced by stopping to reject H0 whenever P1 < c for a value of c > c®. The
conditional error function is
˜ A(p1) =
8
> > > > <
> > > > :
1 for p1 · c;
c®=p1 for c < p1 < d;
0 for p1 ¸ d:
Here c® = exp(¡1
2 ¢Â2
4(®)) as before, c® < c < ® and ® < d < 1. The constants c and d must satisfy
® = c + c® ¢ (logd ¡ logc) to ensure the overall signiﬁcance level (the area under the ˜ A curve) is
still ®. Table 1 of Bauer and K¨ ohne (1994) gives pairs (c;d) meeting these conditions for selected
values of ® = 0:01, 0.025, 0.05 and 0.1.
The analogous modiﬁcation of the weighted inverse normal test that allows both possibilities of
rejection or acceptance of H0 after only considering P1 has conditional error function
˜ A(p1) =
8
> > > > <
> > > > :
1 for p1 · c;
Φ
³p
r Φ¡1(1¡p1)¡z(®) p
1¡r
´
for c < p1 < d;
0 for p1 ¸ d:
13Figure 3: Truncated rejection regions for inverse normal test
0.5 1
0
0.5
1
P
1
P
2
c d
Accept H
0
Reject H
0
Area = α
Area = 1−α
(a) using probability (P) scale (b) using probit (Z) scale
−1 a b −2
−1
1
2
1 2
Z
2
Z
1
Reject H
0
To ensure that the area under the ˜ A curve equals the speciﬁed ®, the constants c and d must be
chosen so that
® = c +
Z d
c
Φ
Ãp
rΦ¡1(1 ¡ p) ¡ z(®)
p
1 ¡ r
!
dp:
The rejection regions on the probability (P) scale and on the probit (Z) scale are shown,
respectively, in the left and right panels of Figure 3. In the right panel, the critical values a
and b are deﬁned by
a = Φ¡1(1 ¡ d) and b = Φ¡1(1 ¡ c): (9)
Hence, with only the results (P1 or Z1) of the ﬁrst study at hand, if Z1 ¸ b we may reject H0 or if
Z1 · a we can immediately declare the results as non-signiﬁcant and abandon the second study as
futile. Only if a < Z1 < b do we need to look at the results of the second study and then we reject
H0 when
p
rZ1 +
p
1 ¡ rZ2 ¸ z(®).
We now return to the situation of Section 3 in which the data could be viewed as i. i. d. normally
distributed. We take K = 2 but instead of viewing the data as arising from two studies or from two
centers, we consider the data as coming from two successive stages of a single group sequential trial.
Suppose also that we agree to use the weighted inverse normal test with weights proportional to the
square roots of the group sizes. In the notation of the current section, this implies r = m1=n and
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1¡r = m2=n. With curtailment, the trial stops early at the ﬁrst stage if Z1 · a or Z1 ¸ b, otherwise
it continues to the second stage where H0 is rejected only if Z = (
p
m1 Z1 +
p
m2 Z2)=
p
n ¸ z(®).
As noted in Section 3, for this weighting the ﬁnal Z-value coincides with the overall Z-statistic for
the total sample given by (5). This means that the rejection plan of Figure 3(b) can be displayed
in the alternative fashion shown in Figure 4. Here the horizontal axis represents cumulative sample
size (m1 or n = m1 + m2) and the vertical axis, labelled Z, is the standardized Z-statistic, Z1 at
the ﬁrst stage or Z at the second stage, based on the cumulative sample at each point.
It can be seen that Figure 4 is the more familiar representation of a discrete boundary for a
conventional group sequential test, in this case with K = 2 stages. For a general group sequential
test, the critical value for Z at the second stage need not equal z(®) — the requirement of all
boundary points taken together is that the total probability under H0 of rejecting H0 should
equal ®. Of course, for K ¸ 3, representations such as those in Figures 1, 2 and 3 are more
15awkward because the rejection regions are subsets in K-dimensional space. On the other hand, if
we are in the situation of Section 3, the discrete boundary representation as shown in Figure 4 is
easily generalized to K ¸ 3; see, for example, the cover diagram (also Figure 4.2) of Jennison and
Turnbull (2000). The correspondence between the two representations exists only if the weighted
inverse normal combination method is used with weights proportional to the square roots of the
group sizes. This combination rule has, therefore, special signiﬁcance as it produces tests in which
decisions are functions of the suﬃcient statistics at each stage and, if the critical values are chosen
correctly, tests can coincide with the optimal group sequential tests of Eales and Jennison (1992)
and Barber and Jennison (2002).
It is a standard assumption in group sequential designs that group sizes are not allowed to
depend on the results of previous stages. If group sizes do have such dependence, the overall
Type I error rate ® of a standard group sequential test may no longer be maintained, just as
we saw for combination tests in Section 3. It is, however, possible to generalize group sequential
designs to allow a pre-speciﬁed dependence of group sizes on observed data, selecting critical values
to give overall Type I error probability ®. Such adaptive group sequential designs were proposed
by Schmitz (1993) and Jennison and Turnbull (2004, 2005) have studied the eﬃciency gains they
can provide relative to non-adaptive designs — ﬁnding the gains to be slight and unlikely to justify
the extra complexities of the adaptive designs. Another reason for wishing to modify a study is
to respond to new developments, internal or external to the study, which alter the investigators’
objectives. Such adaptation can be achieved without aﬀecting the Type I error probability, the key
requirement being that the conditional Type I error probability should be maintained under the
modiﬁed design; see Denne (2001) and M¨ uller and Sch¨ afer (2001). Thus, the function ˜ A(p1) plays
a key role but now it is deﬁned implicitly by the original design, as stated in the trial protocol. We
shall discuss the use of such unplanned mid-course adaptations in the example of Section 6.
5 Example 1: Seamless transition between Phase IIb and
Phase III trials
A phase IIb trial is used in some drug development programs to choose one of several dose levels
while also comparing this set of treatments with an active control or placebo. The dose selected
16will be studied in Phase III: it may be chosen on the basis of the best response on the primary
endpoint or, particularly for cancer treatments, it may be the highest dose that can be tolerated
without serious toxicity. Before embarking on the Phase III study, investigators have the chance
to modify details of the treatment and, if appropriate, re-deﬁne the primary response.
It is highly desirable to avoid delay between the end of a Phase IIb trial and the start of the
subsequent Phase III trial. One way to streamline the process is to present both trials in a combined
protocol. It may also be permissible to combine evidence of treatment beneﬁt from the Phase IIb
and Phase III trials. We shall illustrate how methods described earlier in this paper can be used
in this context.
Consider a study of a new treatment for cholesterol reduction in which 3 dose levels of the
new treatment are to be compared against a placebo control in Phase IIb. The study will enlist
a total of 100 patients, the response for each being the reduction in serum cholesterol over an 8
week period. A trend test will be used to test for a treatment eﬀect, linear in dose level. The null
hypothesis at this stage is that there is no treatment eﬀect at any dose, and this is tested against
the alternative of a linear increase in eﬀect with dose level, the one-sided P-value of this test being
converted into a Z-value, Z1. Although the whole investigation may be abandoned if no treatment
eﬀect is seen at any dose, this decision is likely to depend on the eﬀects observed at each dose level
as well as the linear trend statistic, Z1. We shall not, therefore, attempt to formalize the decision
to abandon the process after Phase IIb but we note that assuming continuation on to Phase III for
all values of Z1 introduces some conservatism into the overall Type I error rate.
The natural choice of dose for evaluation in the Phase III trial is the level producing the greatest
reduction in serum cholesterol in Phase IIb but investigators are free to consider other aspects of
treatment or response in making this choice. We suppose the Phase III trial is run as a two-sample
comparison, again taking reduction in serum cholesterol over 8 weeks as the primary endpoint. The
null hypothesis for this trial is that there is no diﬀerence between the selected treatment and the
placebo control, tested against the alternative of a beneﬁcial treatment eﬀect at this dose. For now,
suppose this trial has a ﬁxed sample size of 200 subjects and a one-sided t-test is carried out giving
P-value P2, which converts to the Z-value Z2.
Data from the two phases are combined in the overall test statistic
Z = w1Z1 + w2Z2
17where the positive weights w1 and w2 are speciﬁed in the joint protocol, before the Phase IIb trial
starts, and satisfy w2
1 + w2
2 = 1. Overall, the null hypothesis tested is the intersection of null
hypotheses for the two stages, which in this case is the null hypothesis for the Phase IIb trial, H0:
no treatment eﬀect at any dose level. If the overall Type I error probability is set at ®, then H0 is
rejected if and only if Z > z(®).
Note that if the overall null hypothesis is rejected, there is still work to do in arguing that the
dose tested in Phase III, which was selected in a data-dependent way, delivers a beneﬁcial eﬀect.
Ideally, one would like to be able to point to evidence in the Phase IIb data of a linear dose-response
so that, under simple model assumptions, positive contributions from other dose levels to Z1, and
hence to the combined statistic Z, lend support to an eﬀect at the selected dose.
Within this framework, there is considerable ﬂexibility.
1. Changes can be made to the deﬁnition of treatment or response for the Phase III trial. There
may, for example, be minor changes to the way the treatment is administered. In deﬁning the
response, analysis of Phase IIb data could suggest that reduction in serum cholesterol occurs
over a diﬀerent timescale and the 8 week period may be replaced by a longer or shorter
interval.
2. It is possible to add a formal rule that the whole sequence of studies stops with acceptance
of H0 if Z1 < a after the Phase IIb trial. Then, the threshold for Z to be signiﬁcant can
be re-calculated to give overall Type I error rate equal to ®. This is an example of a test
allowing curtailment at stage 1, as discussed in Section 4, but in this case only early stopping
for futility is permitted. A drawback of this approach is that, since this early stopping is
only for a negative outcome, the critical value for Z will now be lower than z(®) and it may
be diﬃcult to make the case that a Z-statistic below z(®) represents signiﬁcant evidence
at level ®. Furthermore, there is no guarantee that a formal rule will be adhered to: if
the Phase IIb data show a non-linear dose response, investigators may wish to continue to
Phase III on the strength of good results at one dose level, despite a low trend statistic, Z1.
3. If the response variance observed in Phase IIb data diﬀers substantially from that anticipated,
the sample size of 200 for Phase III may be adjusted to maintain desired power at a speciﬁc
eﬀect size.
184. The Phase III trial may be monitored group sequentially; see Jennison and Turnbull (2000,
Sec. 4.4) for a description of group sequential, one-sided t-tests. One could simply run the
Phase III trial according to a group sequential plan with Type I error rate 0.05, say, then
the overall conclusion would be to reject H0 if the one-sided P-value on termination, P2,
corresponds to a Z-statistic, Z2, satisfying
w1Z1 + w2Z2 > z(®):
For computation of P-values upon termination, see Jennison and Turnbull (2000, Sec. 8.4).
For H0 to be rejected, we need
Z2 >
z(®) ¡ w1Z1
w2
i.e.,
P2 < p(Z1) = 1 ¡ Φ¡1
½
z(®) ¡ w1Z1
w2
¾
:
Given that the output of Phase III will be used in this way in reaching the overall conclusion,
it makes sense to conduct the Phase III trial as a group sequential test with Type I error
probability p(Z1). Then, the one-sided P-value on termination will be less than p(Z1) if
and only if this test rejects its null hypothesis. In this formulation, the outcome of the
Phase III trial has been made to agree with the overall conclusion. Eﬃciency will be served
by creating a group sequential stopping rule which leads to as early a decision as possible in
the Phase III trial to accept or reject the null hypothesis. This is an example of recursive
design, as discussed in Section 2
5. Ideally, accrual should switch straight from Phase IIb to Phase III so that all eligible patients
can be entered into one or other study as they present themselves for treatment. There is
a diﬃculty in doing this since it will take at least 8 weeks from the end of accrual before
all the Phase IIb responses are known. Rather than allow a hiatus in accrual, we propose
making a choice of the treatment for the Phase III trial using the phase IIb data available
when the the Phase IIb recruitment period ends. Follow-up data will continue to come in
and this will be included in the calculation of Z1 in the usual way. The delay in learning the
value of Z1 is another reason against having a formal rule to stop for futility if Z1 < a. Group
sequential monitoring of Phase III, as described in item 4, is still feasible. The key point is
to start Phase III accrual promptly, keeping study monitors blind to any Phase III data until
19the Phase IIb follow-up is completed and a group sequential stopping rule for Phase III has
been decided. Given the complexity of this scheme, it is desirable to specify a template of
the Phase III design as fully as possible in the overall protocol. For example, the type of
group sequential test and frequency of monitoring could be stipulated, ready for the required
Type I error rate, p(Z1), to be incorporated as soon as it is known.
It is clear that this approach is only practical if accrual periods in both Phase IIb and Phase III
trials are long in comparison to the response time. If not, too few of the Phase IIb responses
will be available to make a good choice of treatment for Phase III, or the ﬁrst interim analysis
in Phase III will be later than desired due to the delay in completing the analysis of Phase IIb
data — which has to be done before the Phase III group sequential design can be ﬁnalized.
However, where the approach is feasible, the continuity between the two phases oﬀers an
opportunity to make signiﬁcant gains.
6 Example 2: Mid-course adaptation within a Phase III trial
6.1 Initial formulation
We consider a Phase III trial designed to achieve Type I error rate ® and power 1 ¡ ¯ when the
true treatment eﬀect is equal to ±. This could, quite possibly, be part of a sequence of studies,
as described in Section 5. The Phase III trial could be a ﬁxed sample size study or it could be
planned with a group sequential design. There is now a range of methods in the literature that
allow investigators to re-consider the trial design at an interim point and, if desired, modify the
remaining part of the trial. In a group sequential trial, it is natural to do this at one of the planned
interim analyses. In a ﬁxed sample study, reasons may still arise to consider a design change at an
intermediate point, possibly following an unplanned inspection of the data gathered thus far. We
shall relate some of the proposals for adaptive re-design to the meta-analysis formulation, discuss
what such adaptive modiﬁcations can achieve, and comment on the advantages and disadvantages
of their use in various situations.
As a speciﬁc example, we shall consider a two treatment comparison with responses XAi »
N(¹A; ¾2) on treatment A and XBi » N(¹B; ¾2) on treatment B, where the treatment eﬀect is
20taken to be µ = ¹A ¡ ¹B. A ﬁxed sample size study needs a sample size of
nf = fz(®) + z(¯)g22¾2=±2
per treatment arm to meet the Type I error rate and power requirements described above.
In a group sequential version of this design, analyses may be performed after groups of g
observations per treatment. At the kth analysis, the Z-statistic based on all the data collected
thus far is calculated and the study stops to accept H0 if Zk < ak or to reject H0 if Zk > bk. The
maximum number of groups K is ﬁxed and the group size g and critical values (ak;bk), k = 1;:::;K,
are chosen to ensure the required Type I error rate and power at µ = ± are attained. The maximum
sample size per treatment arm, gK, is equal to Rnf where R > 1 is termed the “inﬂation factor”
and its value depends on the form of testing boundary and maximum number of analyses, K; see,
for example, Jennison and Turnbull (2000).
6.2 Connections between adaptive designs and meta-analysis
Bauer (1989) and Bauer and K¨ ohne (1994) propose a method for modifying the design when a study
is already in progress. An interim point at which modiﬁcations can be made is speciﬁed in the
study protocol, as is a rule for combining the P-values, P1 and P2, calculated from data obtained in
the two parts of the study, either side of this interim point. These authors use the inverse Â2 rule
but any other rule is allowable, as long as it is pre-speciﬁed. This method of combining two sets of
data has a clear interpretation as a meta-analysis of the two sub-studies. Since, in the continuous
case, the P-value P2 has a U(0;1) null distribution, conditional on the outcome of the ﬁrst part of
the study (see Section 2), the combination rule remains valid after the re-design. This approach
provides ﬂexibility for investigators to modify aspects of the study at the interim re-design point:
the treatment may be reﬁned, dosage may be adjusted, even the response variable may be altered.
Such changes parallel the evolution of a treatment seen over the course of a sequence of separate
studies but allowing this to happen within a single trial oﬀers the prospect of more rapid treatment
development.
A more challenging problem is to preserve the Type I error rate when making mid-course design
changes if this eventuality was not considered in the original plan. Consider ﬁrst the case of the
ﬁxed sample study described above with nf = 100 and suppose there is reason to modify the design
21after observing m1 subjects on each treatment. Deﬁne the Z-statistics from current and future data
Z1 =
Pm1
1 (XAi ¡ XBi)
p
m12¾2 and Z2 =
P100
m1+1 (XAi ¡ XBi)
p
m22¾2 ;
where m2 = 100 ¡ m1. In the ﬁnal analysis originally planned, the Z-statistic is
Z =
P100
1 (XAi ¡ XBi)
p
100 ¢ 2¾2 =
p
m1 Z1 +
p
100 ¡ m1 Z2 p
100
(10)
and H0 is rejected if Z > z(®). The P-values for the two parts of the data are P1 = 1 ¡ Φ¡1(Z1)
and P2 = 1 ¡ Φ¡1(Z2) and, in terms of these P-values, the ﬁnal decision is to reject H0 if
p
m1 Φ(1 ¡ P1) +
p
100 ¡ m1 Φ(1 ¡ P2)
p
100
> z(®): (11)
Thus, a combination rule for P1 and P2 is implicit in the original plan and the “meta-analysis
approach” can be followed using this rule. Speciﬁcally, design modiﬁcations can be made after
observing the ﬁrst m1 observations per treatment; for example, the total sample size can be
increased beyond the originally planned nf = 100. The P-value P2 is calculated from the data
collected after this re-design point and this is combined with P1 using the rule (11), keeping these
original weights.
The equivalent representations of the combination rule discussed in Section 4 are also applicable.
The decision rule can be represented as a critical region C for the pair (P1;P2), that is, H0 is rejected
if and only if the pair (P1;P2) lies in C. Alternatively, if the function ˜ A(P1) deﬁnes the boundary
of the critical region, H0 is rejected if P2 < ˜ A(P1). As we saw in Section 4, ˜ A(P1) is the conditional
Type I error probability given the observations at the re-design point and this gives rise to a simply
stated principle for re-design: ﬁrst calculate the current conditional Type I error probability if the
study were to continue following the originally speciﬁed design, ˜ A(P1), then conduct the remainder
of the study with whatever modiﬁcations are deemed appropriate and reject H0 at the end if the
P-value for the remainder of the study, taken by itself, is less than ˜ A(P1).
Using (10), we can just as easily work with Z-statistics and derive a critical value for the
standardized statistic Z2 based on the data from the remainder of the study. In our example, H0
is rejected if
w1Z1 + w2Z2 > z(®)
where w1 =
p
gm1=100g and w2 =
p
f(100 ¡ m1)=100g, and the criterion for rejecting H0 is
Z2 > fz(®) ¡ w1Z1g=w2:
22This approach to mid-course design changes is by no means limited to such simple examples but
generalizes readily to other response types and test statistics. It also encompasses modiﬁcations
during a group sequential trial. Suppose a trial is being conducted according to the group sequential
design outlined in Section 6.1, the trial has continued up to analysis ˜ k where the statistic Z˜ k lies
in the continuation region (a˜ k;b˜ k), and re-design is considered at this point. It is possible to
work in terms of P-values, P1 based on data up to analysis ˜ k and P2 on data from analysis ˜ k
onwards, and identify the critical region C of pairs (P1;P2) for which H0 is rejected. However, the
account given by M¨ uller and Sch¨ afer (2001) shows this approach is complex and the construction
is not particularly intuitive. It is simpler to move straight on to the equivalent deﬁnition in terms
of conditional Type I error probability, ˜ A(P1). This is the probability under H0 that the fZkg
process, starting at the current value of Z˜ k, will cross the upper boundary by analysis K, and it is
easily found using standard group sequential calculations. The remainder of the study can be run
as a new group sequential test with Type I error probability ˜ A(P1) incorporating whatever design
changes are desired. A real advantage of this construction is that it allows investigators to make
an initial choice of an eﬃcient group sequential design knowing that under normal conditions this
will be used throughout the trial but there is the reassurance that, if necessary, it will be possible
to make modiﬁcations in a way that preserves the Type I error rate.
Other methods for adapting group sequential designs ﬁt into this framework. In the proposal by
Cui et al. (1999), group sizes after the re-design point are multiplied by a factor chosen to increase
power and the original boundary values (ak;bk) are applied to modiﬁed versions of the usual Z-
statistics. The authors give a direct proof that the overall Type I error probability is preserved but
it can also be seen that the method preserves the conditional Type I error probability. In fact, this
conditional property must hold by the argument of Jennison and Turnbull (2003, Sec. 3.2) which
implies that any unplanned mid-course re-design that maintains the overall Type I error rate must
preserve the conditional Type I error probability whenever re-design occurs.
The “variance spending” scheme proposed by Shen and Fisher (1999) is described in terms of
Z-statistics. This method starts with a ﬁxed sample test and at a re-design point the criterion for
this test to reject H0 is written as w1Z1 + w2Z2 > z(®) where w2
1 + w2
2 = 1, Z1 is the Z-statistic
summarising current data and Z2 is the Z-statistic still to come from future data. The basic design
modiﬁcation is to change the sample size on which Z2 will be based and to use the Z-statistic based
23on this new sample size in the original rule. Applying such a change recursively gives a form of
group sequential test.
6.3 Merits of various uses of re-design
Many diﬀerent reasons have been given for why investigators may wish to make mid-course design
modiﬁcations. Some of these appear more reasonable than others and in investigating some
proposals we have found a danger of producing seriously ineﬃcient experimental designs. We
conclude this paper with a description of ﬁve commonly cited reasons for design modiﬁcation and
oﬀer our views on the merits of each.
1. Changes in response to external factors. An example is the withdrawal of a competing product
which leaves a gap in the market. If this had been known earlier, a smaller treatment eﬀect
could have been deemed clinically beneﬁcial and there would also have been good ﬁnancial
motivation for a larger study, able to detect a smaller eﬀect size. When such information
arrives during the course of a study, it is reasonable to enlarge the current study in order to
increase power at smaller eﬀect sizes. If the people making this decision are not completely
blind to the data accumulated thus far, it is advisable to make any sample size change in a
manner that maintains the Type I error rate in order to preserve the study’s credibility. The
methods described in Section 6.2 allow such changes to be made. Clearly, it is unfortunate
that the relevant information should not have been known sooner as it would have been
simpler to plan a larger, more powerful study at the outset. But, when information arrives
during a study it is very valuable to have methods available that allow adaptation to changed
objectives.
2. Responding to internal factors: nuisance parameters. For some studies it is diﬃcult to
calculate the sample size needed to satisfy a power requirement as this depends on unknown
factors such as the variance of normal responses or the baseline hazard rate and censoring
rates for survival data. Information on such factors will accrue during the course of a study
and, if initial estimates have been oﬀ target, it is good to be able to adjust the sample size
later. Adaptive methods provide a framework for doing this. Since this problem is likely
to be recognized in advance, these modiﬁcations may be pre-planned. In the case of normal
responses with unknown variance, t-statistics calculated from the data in each stage can be
24converted to exact P-values so the Type I error rate is attained precisely. It should be noted
that there are other ways of coping with the problem of nuisance parameters: there is a large
literature on internal pilot designs (see, for example, Wittes and Brittain (1990) and further
references in Jennison and Turnbull (2000, Chap. 14)) or, in group sequential applications,
error spending tests with maximum information designs (Jennison and Turnbull (2000, Chap.
7)) provide a good solution.
3. Responding to internal factors: safety variables. Several authors mention the impact that
information on the new treatment’s safety can have on the suitability of a study’s power
objective. One possibility is that evidence of good safety properties for the experimental
treatment could indicate that high power should be sought at a lower eﬀect size than that
originally used in setting the study’s power. This would require an increased sample size and
adaptive methods provide a means to do this. Another conclusion might be that, with good
safety outcomes, it should suﬃce to demonstrate non-inferiority, rather than superiority, of
the new treatment. This corresponds to shifting the power curve along the eﬀect size scale:
this may not need a change in sample size but could prompt a change to the group sequential
stopping rule being applied to the primary endpoint. A problem here is that it is not a
requirement that the original Type I error rate should be preserved at the null hypothesis of
zero eﬀect size; so the adaptive methods we have described do not solve the relevant problem.
Of course, interim results on safety are subject to sampling variability and one should be
wary of basing substantial design changes on noisy information. An alternative is available
in Jennison and Turnbull’s (1993) group sequential tests for bivariate data which formally
monitor both safety and eﬃcacy outcomes together.
4. Rescuing an under-powered study. The example Cui et al. (1999) present to motivate their
work concerns a study of a treatment designed to reduce the risk of myocardial infarction in
patients undergoing coronary artery bypass graft surgery. Initially, the investigators hoped
for a reduction in incidence of 50% and the study was designed to achieve 95% power in this
case. Interim data showed a smaller decrease in incidence of around 25% which was still a
worthwhile improvement both clinically and commercially. At this late stage, it became clear
that an increase in power at smaller eﬀect sizes was desirable, but at the time there were
no methods to implement such a change. Methods now available would have allowed this
25modiﬁcation to be made while safeguarding the Type I error rate.
With hindsight, the simple solution would have been to design the study with a larger sample
size and higher power at the outset, avoiding the need for a mid-course design change. We
would certainly recommend that investigators think through scenarios with disappointing
results in advance to gain a fuller understanding of what they really wish to see in a study’s
power curve. Then, they can choose a design achieving the correct objective from the start.
This approach should yield beneﬁts of lower expected sample size as modifying a study’s
objectives in mid-course leads to ineﬃcient procedures: see Jennison and Turnbull (2004b,
Sec. 2.3). However, the number of accounts of under-powered studies suggests this problem
will continue to occur and, while it does, the availability of adaptive methods will be valuable.
5. Responding to internal information on the primary endpoint. Whereas we have presented the
increase of sample size in an under-powered study as a “rescue” process with implicit criticism
of the poor initial design, some authors view the ﬂexibility of adaptive procedures as a positive
advantage and advocate their use to modify power as new estimates b µ of the eﬀect size are
obtained. It may well be that modifying an initial ﬁxed sample size procedure yields an overall
adaptive scheme with higher power but a smaller increase in average sample size than the
ﬁxed sample test needed to achieve this power: the examples Proschan and Hunsberger (1995)
give of their “designed extension procedure” illustrate this point. However, if the adaptive
procedure has two stages, the appropriate comparison is with a group sequential test with
K = 2 analyses and in this comparison the Proschan and Hunsberger (1995) designs prove
inferior.
We remarked in Section 4 that there is a well developed methodology for constructing group
sequential tests optimized to speciﬁc criteria. These designs use the sequence of estimates b µ in
their stopping rules and, by deﬁnition searching for new types of group sequential procedure
to beat the optimum tests is futile. The freedom to let group sizes depend adaptively on
current data does represent a possible source of improved eﬃciency but calculations reported
by Jennison and Turnbull (2004, 2005) show the beneﬁts of this to be insigniﬁcant. On the
other hand, it is quite possible that adaptive schemes deﬁned with what appear to be sensible
sample size rules and stopping rules may be substantially less eﬃcient than optimal group
sequential tests with the same number of analyses. We have assessed a number of adaptive
26schemes described in the literature in terms of their overall power curves and average sample
size functions, and found a high proportion to be quite ineﬃcient. Given the availability
of simply deﬁned, eﬃcient group sequential tests (Jennison and Turnbull (2005)), our simple
recommendation is to look no further. If, for some reason, an adaptive scheme really is deemed
desirable, we suggest that its power curve and average sample size function be computed and
compared against a standard group sequential design to make sure it has adequate eﬃciency.
Overall, our conclusion is that the key advantages of adaptive methods are (a) the ability to make
mid-study modiﬁcations in response to external factors or, possibly, internal information on safety
outcomes and (b) the ability to rescue an under-powered study when this problem becomes apparent
during the study. These adaptations can be implemented in ﬁxed sample and group sequential tests
and, by ensuring the conditional Type I error probability remains unchanged, the overall Type I
error rate will be maintained. On the other hand, we see no point in pursuing varieties of adaptive
design as a novel alternative to standard group sequential tests: simple and highly eﬃcient designs
are already known and well understood and, unless the adaptive designs have other advantageous
features, the very best they will do is gain equality with existing methods.
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